Which is more justified for the treatment of CML patients in developing countries, HSCT or TKIs?

Emerging Markets Comments (0)

Which is more justified for the treatment of CML patients in developing countries, HSCT or TKIs?

Tyrosine kinase inhibitors have revolutionized CML treatment but the cost is considered a very big obstacle in developing countries. Taking cost into …
see full story

» Emerging Markets » Which is more justified for...
On July 25, 2014
By
,

Leave a Reply

Your email address will not be published. Required fields are marked *

« »